Telix Pharmaceuticals Limited (TLX,TLX.AX) reported that its group revenue for the first quarter of fiscal year 2016 increased about 24% to US$230 million, from US$186 million last year.
Precision Medicine revenue for the quarter were US$186 million, up 23% from prior year.
The company reaffirmed its revenue guidance for fiscal year 2026 in a range of US$950 million to US$970 million.
TLX.AX was trading at A$13.54 up A$0.59 or 4.56%.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.